Caregivers are often a very important part of a person’s fight against myelodysplastic syndromes (MDS). Patients need to focus on their health and may not be well enough to drive themselves to doctor appointments or to keep up with house chores. They also need someone that they can talk to about treatment options and about the emotional roller coaster they may be experiencing.
Patients lean or even depend on their caregiver, and yet as a caregiver, you are also going…
Vidaza (azacytidine) may be as effective and well tolerated in myelodysplastic syndromes (MDS) patients aged 80 years and above as compared to patients less than 80 years old, according to a retrospective analysis by French researchers.
The findings were presented at the 51st Annual American Society of Hematology (ASH) meeting and exposition in December.
MDS patients aged 80 years and above make up 30 to 35 percent of all MDS patients. These patients are usually not candidates for chemotherapy, even…
Dacogen (decitabine) is an effective and well-tolerated treatment for older myelodysplastic syndromes (MDS) patients, according to findings presented at the 51st Annual American Society of Hematology (ASH) meeting on December 6.
The risk of developing MDS increases with age, and older patients make up a large share of all MDS patients. Older cancer patients, however, often find it particularly challenging to deal with the side effects of many cancer drugs.
For these reasons, physicians who treat MDS are particularly interested…
Vfend (voriconazole) may be an effective alternative to Sporanox (itraconazole) in the prevention of fungal infection in myelodysplastic syndromes (MDS) according to researchers at the University of Texas MD Anderson Cancer Center.
The research results were published in the official journal of the Multinational Association of Supportive Care in Cancer.
Infections are a serious risk to MDS patients undergoing treatment. Many physicians prescribe antibiotics or antifungal treatments preemptively to prevent infections from developing during MDS treatment.…